

3 November 2025

NEW EMPLOYEE INCENTIVES

EVE Health Group Limited (ASX: EVE, EVE or the Company) advises that the board of directors has resolved to issue up to 12,300,000 unlisted options to key personnel and directors of the Company under the terms and conditions of the Company's Employee Incentive Plan

The options form part of revised remuneration and retention arrangements and are intended to align at-risk compensation with value creation for shareholders, support talent retention in a competitive market, and focus the team on key commercial and regulatory milestones across the Company's women's and men's health portfolios.

Up to 11,000,000 options will be offered to employees and 1,300,000 options to directors, as tabled below. Director grants will be subject to shareholder approval at a shareholder meeting.

Name	Role	Options
Rod Hannington	Non-Executive Chair	150,000
Stuart Gunzburg	Chief Scientific Officer / Executive Director	1,000,000
Bill Fry	Non-Executive Director	150,000

Key terms of Director options

- Exercise price: \$0.06 per share (the same price as the options attaching to the recently completed placement)
- Expiry: 3 years from grant
- Vesting: subject to service conditions and performance hurdles comprising share price milestones (7.5c, 15c and 30c sustained for 10 consecutive trading days within specified dates), full TGA registration of Dyspro™ and Libbo™, and achievement of group gross revenue targets for FY26–FY28.

Authorised for release by the Company Secretary.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.